| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 17.40 | 4.76% | 68.39万 | 11.79亿 | | | 688098 | 申联生物 | 9.67 | 1.90% | 6.49万 | 6219.61万 | | | 600195 | 中牧股份 | 8.10 | 1.25% | 13.81万 | | 1.11亿 | | 300119 | 瑞普生物 | 19.90 | 1.12% | 1 5.47万 | | 1.08亿 | | 603718 | 海利生物 | 6.48 | 0.78% | 12.46万 | 8036.77万 | | | 300871 | 回盛生物 | 22.63 | 0.76% | 8.39万 | | 1.89亿 | | 002688 | 金河生物 | 6.18 | 0.65% | 13.29万 | 8173.65万 | | | 920970 | 大禹生物 | 8.07 | 0.62% | 1.81万 | 1461.12 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002141 | 赔丰控股 | 3.73 | -2.61% | 18.27万 | - 6847.05万 | | 300119 | 瑞普生物 | 18.77 | -2.19% | 5.43万 | 1.03亿 | | 688526 | 科前生物 | 15.26 | -0.65% | 1.80万 | 2751.28万 | | 603566 | 普莱柯 | 12.43 | -0.56% | 1 2.58万 | 3214.77万 | | 920970 | 大禹生物 | 7.69 | -0.39% | 1.46万 | 1123.72万 | | 603718 | 海利生物 | 6.10 | -0.16% | 6.35万 | 3877.59万 | | 600195 | 中牧股份 | 7.87 | -0.13% | 7.48万 | 5877.61万 | | 920275 | 驱动力 | 8.71 | -0.11% | 8083.76 | 705.65万 | | 92 ...

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

Group 1 - The core point of the news is that Yongshun Biological (920729) has seen a net financing inflow of 25.57 million yuan on October 29, 2025, with a total financing balance of 1,300.67 million yuan, indicating a positive trend in investor interest [1][2][3] - Over the past three trading days, the cumulative net buying has reached 57.1 million yuan, reflecting a consistent increase in financing activity [1] - The financing balance increased by 2.01% compared to the previous day, showing a growing confidence among investors [2][3] Group 2 - The financing net buying on October 28 was 11,700 yuan, and on October 27, it was 303,600 yuan, indicating fluctuations in investor activity [2] - The financing balance on October 24 was 1,243.57 million yuan, which decreased by 21,170 yuan, highlighting a brief period of reduced investor engagement [2][3] - The overall margin trading balance on October 29 was 1,300.67 million yuan, marking a significant increase in trading activity [3]

Core Viewpoint - Yongshun Biological has demonstrated strong operational resilience with a slight increase in net profit despite a decrease in revenue, indicating effective cost control and product optimization strategies [1][2]. Financial Performance - In the first three quarters of 2025, Yongshun Biological achieved operating revenue of 180 million yuan, with a net profit attributable to shareholders of 30.28 million yuan, reflecting a year-on-year growth of 4.56% [1]. - The company's operating income decreased by 10.18% year-on-year, attributed to the cyclical fluctuations in the pig farming industry [2]. - The net cash flow from operating activities reached 74.66 million yuan, a significant increase of 34.97% year-on-year, indicating strong cash flow management [2]. - Asset impairment losses were reduced by 75.49% year-on-year, primarily due to improved inventory turnover and efficiency [2]. Product Development and Innovation - Yongshun Biological has focused on innovation, investing 15.31 million yuan in R&D, which is approximately 8.50% of its operating revenue [3]. - The company has recently obtained production licenses for two significant products: a quadrivalent inactivated vaccine for avian influenza and a bivalent inactivated vaccine for H5 subtype avian influenza, enhancing its market position in poultry vaccines [3]. - Additional product approvals include a new vaccine for pigeon newcastle disease and several other vaccines for swine diseases, indicating a robust pipeline for future growth [3]. Industry Outlook - The pig farming industry is expected to rebound in the fourth quarter, supported by policy adjustments and market corrections, positioning Yongshun Biological favorably for sustained growth in the upcoming industry cycle [4].

Market Overview - The animal health sector increased by 0.81% on October 20, with Xianfeng Holdings leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Xianfeng Holdings (002141) closed at 4.06, up 5.45% with a trading volume of 588,700 shares and a turnover of 237 million yuan [1] - Other notable stocks included ST Lvkang (002868) at 28.36, up 5.00%, and Biological Shares (600201) at 10.95, up 1.48% [1] - The overall trading volume and turnover for the animal health sector were significant, indicating active market participation [1] Capital Flow - The animal health sector saw a net inflow of 31.5863 million yuan from institutional investors, while retail investors experienced a net outflow of 10.9434 million yuan [2] - The main capital inflow was primarily directed towards Xianfeng Holdings, which had a net inflow of 28.5381 million yuan [3] - Conversely, stocks like Shunlian Biological (688088) and ST Lvkang experienced net outflows from retail investors, indicating a shift in investor sentiment [3]

Core Viewpoint - The animal health sector experienced a rise of 0.98% on September 30, with *ST Lvkang leading the gains, while the overall market indices also showed positive movement [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3882.78, up 0.52% [1]. - The Shenzhen Component Index closed at 13526.51, up 0.35% [1]. - The animal health sector's individual stock performance is detailed in a table, highlighting various stocks' closing prices and percentage changes [1]. Group 2: Stock Performance - *ST Lvkang (002868) closed at 28.01, with a gain of 3.51% and a trading volume of 16,700 shares, amounting to approximately 46.61 million yuan [1]. - Other notable stocks include: - Biological Shares (600201) at 9.64, up 1.69% with a trading volume of 412,400 shares [1]. - Jinhe Biological (002688) at 6.69, up 1.67% with a trading volume of 150,600 shares [1]. - KQ Bio (688526) at 17.72, up 1.37% with a trading volume of 32,700 shares [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 3.40 million yuan from institutional investors, while retail investors experienced a net outflow of 28.01 million yuan [2][3]. - The detailed capital flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3]. - For instance, Biological Shares (600201) had a net inflow of approximately 19.60 million yuan from institutional investors, while *ST Lvkang (002868) faced a net outflow of about 6.49 million yuan [3].

Core Insights - The animal health sector experienced a slight increase of 0.46% on September 29, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Shenlian Biological (688098) closed at 10.59, up 1.92% with a trading volume of 68,700 shares and a turnover of 72.32 million yuan [1] - Other notable performers included: - Biological Shares (600201) at 9.48, up 1.50% with a turnover of 503 million yuan [1] - Pulaike (603566) at 13.78, up 1.03% with a turnover of 54.30 million yuan [1] - Zhongmu Shares (600195) at 7.12, up 0.85% with a turnover of 49.02 million yuan [1] Capital Flow - The animal health sector saw a net outflow of 7.69 million yuan from institutional investors, while retail investors contributed a net inflow of 8.08 million yuan [2] - The detailed capital flow for key stocks includes: - Shenlian Biological: net outflow of 5.50 million yuan from retail investors [3] - Biological Shares: net outflow of 7.67 million yuan from retail investors [3] - Pulaike: net outflow of 4.08 million yuan from retail investors [3]

Market Overview - On September 25, the animal health sector declined by 1.62% compared to the previous trading day, with the leading stock, Driveline, experiencing a drop of 4.04% [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - The following stocks in the animal health sector showed notable declines: - Driveline (Code: 838275) closed at 9.50, down 4.04% with a trading volume of 19,300 lots [1] - Shunlian Bio (Code: 688098) closed at 10.43, down 3.43% with a trading volume of 76,300 lots [1] - Yongshun Bio (Code: 839729) closed at 9.74, down 2.89% with a trading volume of 20,800 lots [1] - Other notable declines include *ST Green Health (Code: 002868) down 2.39% and Shoufeng Holdings (Code: 002141) down 2.33% [1] Capital Flow - The animal health sector saw a net outflow of 113 million yuan from institutional investors, while retail investors experienced a net inflow of 61.16 million yuan [1] - The following stocks had significant capital flow: - Zhongmu Co. (Code: 600195) had a net inflow of 986,800 yuan from institutional investors [2] - Pulaike (Code: 603566) saw a net inflow of 764,200 yuan from retail investors [2] - *ST Green Health (Code: 002868) experienced a net outflow of 6.71 million yuan from institutional investors [2]

证券代码：839729 证券简称：永顺生物 公告编号：2025-094 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 广东永顺生物制药股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 活动时间：2025 年 9 月 19 日 15:30-17:00 活动地点：本次活动采用网络远程的方式举行，投资者通过登录"全景路演" 网站（https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流。 参会单位及人员：通过网络方式参与 2025 年广东辖区上市公司投资者网上 集体接待日活动的投资者 上市公司接待人员：公司董事、总经理吴锋先生，副总经理、财务负责人李 秋红女士，副总经理、董事会秘书林建新先生 三、 投资者关系活动主要内容 □现场参观 □新闻发布会 □分析师会议 □路演活动 √其他 (2025 年广东辖区上市公司投资者网上集体接待日活动) 二、 投资者关系活动情况 问题 4：公司提出"渠道下沉、服务终端 ...